187 related articles for article (PubMed ID: 30584254)
1. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.
Ge X; Chen J; Li L; Ding P; Wang Q; Zhang W; Li L; Lv X; Zhou D; Jiang Z; Zeng H; Xu Y; Hou Y; Hu W
Cell Death Dis; 2018 Dec; 10(1):8. PubMed ID: 30584254
[TBL] [Abstract][Full Text] [Related]
2. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
3. Effects of digoxin on cell cycle, apoptosis and NF-κB pathway in Burkitt's lymphoma cells and animal model.
Wang T; Xu P; Wang F; Zhou D; Wang R; Meng L; Wang X; Zhou M; Chen B; Ouyang J
Leuk Lymphoma; 2017 Jul; 58(7):1673-1685. PubMed ID: 28084852
[TBL] [Abstract][Full Text] [Related]
4. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
6. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
8. β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway.
Hu T; Gao Y
Biomed Pharmacother; 2018 Oct; 106():1557-1562. PubMed ID: 30119230
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
10. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
[TBL] [Abstract][Full Text] [Related]
11. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
12. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
Runckel K; Barth MJ; Mavis C; Gu JJ; Hernandez-Ilizaliturri FJ
Blood Adv; 2018 Dec; 2(23):3516-3525. PubMed ID: 30530779
[TBL] [Abstract][Full Text] [Related]
13. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
14. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin.
Shlapatska LM; Berdova GG; Kovalevska LM; Kulyk GI; Klein G; Sidorenko SP; Chekhun VF
Exp Oncol; 2004 Sep; 26(3):210-6. PubMed ID: 15494689
[TBL] [Abstract][Full Text] [Related]
16. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
17. Effect of nucleolin on adriamycin resistance via the regulation of B-cell lymphoma 2 expression in Burkitt's lymphoma cells.
Mei X; Chen Y; Gan D; Chen Y; Wang L; Cao Y; Wu Z; Liu W; Zhao C; Lin M; Yang T; Hu J
J Cell Physiol; 2019 Dec; 234(12):22666-22674. PubMed ID: 31127617
[TBL] [Abstract][Full Text] [Related]
18. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
Bonavida B
Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
[TBL] [Abstract][Full Text] [Related]
20. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.
Barboza NM; Medina DJ; Budak-Alpdogan T; Aracil M; Jimeno JM; Bertino JR; Banerjee D
Cancer Biol Ther; 2012 Jan; 13(2):114-22. PubMed ID: 22336911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
